Page 21 - Flipbook
P. 21
Pembrolizumab Plus Axitinib Versus Sunitinib as First-Line Therapy for Advanced Clear Cell Renal Cell Carcinoma: Results From 42-Month <br />Follow-Up of KEYNOTE-426
Content of this presentation is the property of the author, licensed by ASCO. Permission required for reuse.
